Dr Prakash Baligar

Associate Professor

Amity Institute of Molecular Medicine & Stem Cell Research
 
  • Academic Area

    Molecular Medicine & Biomedical Sciences

    Advance Materials and Devices

    Material Science

    Basic Life Sciences

  • Teaching Interests

    Stem Cell Biology Tissue Engineering
  • Qualifications

    Graduation : B.Sc(Chemistry, Botany & Zoology)-1996,R.T.E.S. College Ranebennur

    Post Graduation : M.Sc(Zoology)-1998,Karnataka University

    Post Graduation : M.Phil(Zoology)-2000,Karnataka University

    Doctorate : Ph.D.(Reproductive Biology)-2002,Karnataka University

  • Experience

    20 Jul 2015 - Present
    Associate Professor,
    Amity Institute of Molecular Medicine & Stem Cell Research

    13 May 2011 - 18 Jul 2015
    Research Associate,
    National Institute of Immunology,
    Delhi

    05 Jul 2007 - 11 May 2011
    Scientist,
    Excel Matrics Biological Divice Pvt. Ltd.,
    Hyderabad

  • Current Courses Taught

    Comprehensive Examination – Biotechnology

    Developmental Biology & Stem Cell Physiology

    Hormone Biochemistry

    Human Pathophysiology

    Professional Ethics and Social Responsibility

    Professional Ethics and Social Responsibility for Sustainability

    Stem Cell Applications in Human Health

    Stem Cell Biology II

    Stem Cells & Gene Therapy

    Tissue Engineering and Regenerative Medicine

  • Research Interests

    Stem Cell Therapy Tissue Engineering Development of Biomaterials Organ Development
  • Publications

    Molecular and cellular functions distinguish superior therapeutic efficiency of bone marrow CD45 cells over mesenchymal stem cells in liver cirrhosis. ,
    Stem cells

    Nonmulberry Silk Fibroin Scaffold Shows Superior Osteoconductivity Than Mulberry Silk Fibroin in Calvarial Bone Regeneration ,
    WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

    Donor antigen-primed regulatory T cells permit liver regeneration and phenotype correction in hemophilia A mouse by allogeneic bone marrow stem cells ,
    BioMed Central

    Bone marrow stem-cell therapy for genetic and chronic liver diseases. ,
    Springer

    Therapeutics Potential of bone marrow-derived stem cells in treatment of genetic diseases of liver. ,
    Springer

    Molecular and Cellular Functions Distinguish Superior Therapeutic Efficiency of Bone Marrow CD45 Cells Over Mesenchymal Stem Cells in Liver Cirrhosis ,
    Stem cells

    Bone Marrow Cells Repair and Regenerate Acute and Chronic Injured Liver without Primary Evidence of Neoplastic Changes ,
    International Journal of Stem Cell Research & Therapy

    Experimental Liver Fibrosis and Intrasplenic Transplantation of CD45 + Bone Marrow Cells ,
    Bio-Protocol

    Role of antigen presenting cell invariant chain in the development of hepatic steatosis in mouse model ,
    Elsevier-Experimental Cell Research

    Bone Marrow Stem Cell Therapy Partially Ameliorates Pathological Consequences in Livers of Mice Expressing Mutant Human a1-Antitrypsin ,
    HEPATOLOGY -Wiley Blackwell

  • Projects

    Ex vivo partial liver organ development by using stem cells and tissue engineering approaches(xxxxx)
    The liver transplantation is the primary option for patients with acute liver failure or end-stage liver diseases. In spite of surgical advancement, this approach has certain draw backs like limited availability of the donor liver and use of immunosuppressive drugs lifelong. However, till date there is no 3D liver ex vivo model for treating many liver diseases and testing of drugs during the clinical development. Therefore, alternative strategies for the treatment of liver diseases are veryby (DST-SERB)

    Ex vivo partial liver organ development by using stem cells and tissue engineering approaches(xxxxxx)
    The liver transplantation is the primary option for patients with acute liver failure or end-stage liver diseases. Various surgical options have been followed to increase the supply of liver including split liver transplants and living-related partial donor procedures. In spite of surgical advancement, this approach has certain draw backs like limited availability of the donor liver and use of immunosuppressive drugs lifelong. However, till date there is no 3D liver ex vivo model for treatby (DST-SERB)

  • Short Description

    I did MSc, PhD. from Karnatak university Dharwad, Karnataka. I have about 10 years of research experience in the field of Stem cells and tissue engineering and 3yeras of teaching experience for the PG student of Biotechnology. I have published 18 publications in the peer reviewed journals, 2 chapters in the Book and 1 US patent in the stem cell therapy. Presently, joined as a asst Prof in Amity university on 20 July 2015 and submitted a project proposal to DST-SERB early carrier research grant award on 28 Sept 2015. And I am teaching for the MSc course of AIMMSCR.